Dimerix (ASX:DXB) has key news flow pending as it remains on-track to release final clinical data for its Phase 2 Dose Escalation study in chronic kidney disease in July.
Interim data released in 2016 was positive and well received by clinicians.
Dimerix will initiate a Phase 2 Dose Expansion study in the second half of 2017.
The company has this week hosted a half-day meeting with representatives from the patient advocacy group NephCure Kidney International and leading nephrologists from the U.S. and Canada.
NephCure is a U.S.-based organisation which supports research into the potentially debilitating kidney disease focal segmental glomerulosclerosis (FSGS), which causes nephrotic syndrome.
Dimerix has received Orphan Drug Designation for the use of DMX-200 in the treatment of FSGS.
Kathy Harrison, chief executive officer for Dimerix, commented:
"Interim data from Part A of the DMX-200 trial for CKD showed a good safety profile and encouraging signs of reduction of proteinuria.
"We are confident that the current patient cohort will support progress to Part B of the study which will focus on the efficacy outcomes at selected doses for the treatment.
"We came away from the Nephcure meeting having achieved our major aims.
"The group made a number of positive suggestions which will assist in guiding the clinical program, and expressed enthusiasm for future involvement in the DMX-200 development program."